May 20, 2015 my husband was diagnosed with multiple myeloma in january. The increasing evidence for clonal diversity and evolution in multiple myeloma highlights the importance of laboratory algorithms that measure both intact immunoglobulins and monoclonal flcs, at diagnosis and when monitoring response to. The serum free light chain assay sflca is a blood test that measures the levels of light chains and can be used to determine al amyloidosis activity and response to treatment. Blood and urine analysis from 5573 newly diagnosed myeloma patients identi. Since the spep measures the levels of intact whole antibodies, it cannot measure the amount of light.
Multiple myeloma early detection, diagnosis, and staging. Comparison of three different serumfree lightchain assays. All the patients werestage iii in the duriesalmonstaging system. The sflca is an important advance in the diagnosis and monitoring of al amyloidosis. Monitor response to treatment sonora quest laboratories. Myeloma cast nephropathy mcn is a common cause of severe renal impairment in multiple myeloma mm.
Abnormal levels of free light chains in the blood can be a sign of multiple myeloma or another serious disorder. Immunoglobulin free light chain ratio is an independent risk. The serum free light chain assay sflca is a blood test that measures the levels of light chains and can be used to determine al amyloidosis activity and response to. The level of free light chain flc that causes mcn varies substantially and there is. Updated diagnostic criteria and staging system for multiple. In particular, free light chain nephrotoxicity accounts for the high prevalence of renal impairment seen in lcmm. Among them, 66 patients received velcade bortezomib treatment.
When a light chain is not attached to a heavy chain, it is known as a free light chain. Light chain multiple myeloma, clinic features, responses to. My husband was diagnosed with multiple myeloma in january. Lightchain myeloma, also known as lightchain disease, is a type of multiple myeloma in which the malignant bone marrow cells produce free monoclonal light chain proteins. Hematologic response is measured using the serum and urine electrophoresis and immunofixation tests, and the free light chain assay.
This study reports the associations between renal function and disease characteristics including serum free light chain flc level at diagnosis in patients with mm. One particularly interesting aspect of serum flcs involves their short halflives in the blood. Jan 15, 2008 an abnormal serum immunoglobulin free light chain flc ratio at baseline could help to further refine prognosis in smm based on the predictive power demonstrated for the flc ratio in patients with other plasma cell disorders. An abnormal serum immunoglobulin free light chain flc ratio at baseline could help to further refine prognosis in smm based on the predictive power demonstrated for the flc ratio in patients with other plasma cell disorders.
Each patient with myeloma has one of the 10 different antibody subtypes as shown in the accompanying table. In 2014, the international myeloma working group imwg updated the diagnostic criteria for mm to add three specific biomarkers that can be used to diagnose the disease in patients who did not have crab features. In addition, it has been the mainstay of diagnosis for disorders such as al amyloidosis and lcmm, in which the. Monoclonal free light chains flcs are important disease biomarkers in patients with plasma cellproliferative disorders. Serum free light chain analysis and urine immunofixation. Clinical manifestation is often heralded by hyperalcaemia, c renal impairment, normocytic normochromic naemia and one lesions, b a. This study aims to guide the integration of serum free light chain sflc tests into clinical practice, including a new rapid test seralite. Light chain multiple myeloma malaysian journal of pathology.
This article is a retrospective study of 142 multiple myeloma patients with 12% having an abnormal serum free light chain ratio but with otherwise no evidence of disease. The immunoassay for quantifying free immunoglobin light chains in serum sflc has been a valuable tool for diagnosing and monitoring lightchain multiple myeloma mm 1. Distributions of k and l flc in normal, multiple myeloma and polyclonal. If the myeloma cells are releasing kappa free light chains, the freelite test will show a high level of kappa light chain protein and a normal, or lower than normal, level of lambda light chains. May 01, 2005 using serum free light chain assays in the myeloma clinic, submitted for publication. L l f flc i t d ith th b flevels of flcs are associated with the number of. As many as 18 percent of all multiple myeloma cancer patients have the lightchain myeloma variety. About 20 out of 100 people with myeloma 20% do not produce complete immunoglobulins. Free light chain results can be converted back and forth in terms of units easily just by dividing or multiplying by 10. The increasing evidence for clonal diversity and evolution in multiple myeloma highlights the importance of laboratory algorithms that measure both intact immunoglobulins and monoclonal flcs, at diagnosis and when monitoring response to treatment. Immunoassay of these light chains has been a reputable diagnostic monitoring modality for light chain multiple myeloma 4. Serum free light chain ratio as a biomarker for highrisk smoldering multiple myeloma.
High serumfree light chain levels and their rapid reduction. If the myeloma cells in the bone marrow are secreting lambda free light chains, then the freelite. The latter, designated as light chain multiple myeloma lcmm makes up almost 20% of myelomas. Serum free lightchain assays have been used in a number of published studies which have indicated superiority over the urine tests, particularly for patients producing low levels of monoclonal free light chains, as seen in nonsecretory multiple myeloma and al amyloidosis.
The most common cause of kidney failure in multiple myeloma is due to proteins secreted by the malignant cells. The immunoassay for quantifying free immunoglobin light chains in serum sflc has been a valuable tool for diagnosing and monitoring light chain multiple myeloma mm 1, amyloid light chain. Prognostic value of serum free light chain in multiple myeloma article pdf available in the egyptian journal of immunology egyptian association of immunologists 222. Imwg guidlines serumfree light chain int myeloma fn. Sebia, a world leader in multiple myeloma diagnostics and monitoring, announces today the launch of two newgeneration serum free light chain assays for multiple myeloma testing. Cureus an overview of light chain multiple myeloma. In all of these abnormal patients the abnormal kappalambda ratio was caused by abnormalities in. Multiple myeloma mm is a prototypic monoclonal bcell malignancy with a terminally differentiated plasma cell phenotype and monoclonal immunoglobulin secretion in the majority of cases.
Pdf prognostic value of serum free light chain in multiple. The total light chain assay is not useful for myeloma patients and can sometimes get confused with the freelite test. Sep 26, 2019 light chain deposition disease lcdd is the deposition of monoclonal light chains in multiple organs. International myeloma working group guidelines for serumfree light chain analysis in multiple myeloma and related disorders. Pdf international myeloma working group guidelines for. We intended to investigate the longterm clinical characteristics, responses to therapy and survival in patients with lightchain multiple myeloma mm. Kappa light chain multiple myeloma treatment mercy. With time, they can also cause bones to weaken and break. Jul 28, 2014 we intended to investigate the longterm clinical characteristics, responses to therapy and survival in patients with lightchain multiple myeloma mm. When abnormal amounts of free light chain bence jones protein are present in urine, they are normally detected by urine protein electrophoresis upep and immunofixation.
Using serum free light chain assays in the myeloma clinic, submitted for publication. Free light chains circulate in the blood atfree light chains circulate in the blood at abnormally highabnormally high levels in many patients with al amyloidosis. Sebia launches newgeneration serum free light chain sflc. After a detailed screening, six studies involving a total of 1054 lcmm patients were included. Combined use of free light chain and heavylight chain ratios allow. Serum free light chains for monitoring multiple myeloma. Living with abnormal free light chain ratios the myeloma.
Significance of serum free light chains in prognosis and. Serum free light chain assays serum free light chain assays freelite are recommended by the nccn clinical practice guidelines in oncology and the international myeloma working group for use in the initial diagnostic workup of multiple myeloma and related disorders. Pdf measurement of serum free light chains flcs has recently become available. With this disorder, theres an overabundance of a specific antibody protein the kappa light chain protein. Renal impairment ri is common in multiple myeloma mm and is associated with poor survival. The two new assays aim to provide more consistent results by overcoming the challenges in analytical performance and coherence. Imwg guidelines for serum free light chain analysis in multiple myeloma and related disorders1 for the more than 3% of myeloma patients who have nonsecretory or oligosecretory disease, and for the majority of. The normal plasmacell production of free light chains is from 0. Potential pitfalls of serum free light chain analysis to assess treatment response for multiple myeloma. It is a malignant disease characterized by abnormal proliferation of plasma cells and monoclonal immunoglobulins or free light chains flc.
Using data from the medical research council myeloma ix trial, a multicentre, randomized, open. Myeloma cells produce monoclonal proteins of varying types, most commonly immunoglobulins antibodies and free light chains, resulting in abnormally high levels of these proteins in the blood. But myeloma cells can cause fatigue, easy bleeding and lowered resistance to infections. Unlinked light chains are sent into the bloodstream and are known as free light chains. In patients with multiple myeloma, the free light chain assay is important in predicting response to therapy and for predicting early signs of relapse, gasparetto says. Since the spep measures the levels of intact whole antibodies, it cannot. Serum free light chain assays have been used in a number of published studies which have indicated superiority over the urine tests, particularly for patients producing low levels of monoclonal free light chains, as seen in nonsecretory multiple myeloma and al amyloidosis. We performed a comprehensive literature search on lcmm and identified a total of 390 articles. This type of myeloma is usually more severe than the classic kind. International myeloma working group guidelines for serum free light chain analysis in multiple myeloma and related disorders. Using data from the medical research council myeloma ix trial, a multicentre, randomized, openlabel, phase iii and factorialdesign. Serum free light chain ratio in correlation with serum protein electrophoresis in. Multiple myeloma mm constitutes for 10% of all hematological malignancies and 1% of all malignancies 12.
Kidney therapy for free light chain removal in patients with. Sserum free light chain infoguide april 2016 dd 7erum free light chain infoguide april 2016 dd 7 221042016 17. Between january 2012 and march 2014, 90 patients were examined. They may also be useful in patients producing intact immunoglobulins. In wm, the range of values is not as extreme as in myeloma.
Apr 03, 2020 light chain myeloma, also known as light chain disease, is a type of multiple myeloma in which the malignant bone marrow cells produce free monoclonal light chain proteins. Mgus, monoclonal gammopathy of undetermined significance flc, free light. As many as 18 percent of all multiple myeloma cancer patients have the light chain myeloma variety. Light chain multiple myeloma lcmm constitutes approximately 15% of patients with multiple myeloma mm. It is a rare disease characterized by deposition of nonamyloid immunoglobulin light chains, and they do not stain with congo red and do not exhibit a fibrillar structure when examined ultrastructurally. After a detailed screening, six studies involving a total of 1054 lcmm patients were. Serumfree light chain analysis for the diagnosis, management. This study will evaluate patients with multiple myeloma and severe renal failure treated with kidney therapy previously called supra hfr to remove free light.
Light chain myeloma sometimes called bence jones myeloma. Serum free light chain analysis for diagnosis, monitoring. Serum free light chain measurements move to center stage. Each plasma cell can make only one type of heavy chain and one type of light chain. They only produce part of the immunoglobulin called the light chain.
Immunoglobulin free light chain ratio is an independent risk factor for progression of smoldering asymptomatic multiple myeloma. This is most helpful in the rare cases of myeloma in which no m protein is found by spep. It has a poorer prognosis when compared to immunoglobulin ig g or iga variant. Imwg guidelines for serum free light chain analysis in multiple myeloma and related disorders for the more than 3% of myeloma patients who have nonsecretory or oligosecretory disease, and for the majority of patients with al amyloidosis al, the traditional methods of measuring circulating monoclonal immunoglobulins electrophoresis.
Hematologic response is measured using the serum and urine electrophoresis and immunofixation tests, and the free lightchain assay. Serum free light chain level at diagnosis in myeloma cast. Light chains are proteins that link up with other proteins called heavy chains to form antibodies. Serum free light chains this blood test can measure the light chain levels in the blood and is done when looking for myeloma or light chain amyloidosis. A serum panel using serum free light chain analysis in combination with either serum protein electrophoresis or serum immunofixation has been shown in several studies to be a highly sensitive approach to screening for most plasma cell disorders. Jan 26, 2009 in patients with multiple myeloma, the free light chain assay is important in predicting response to therapy and for predicting early signs of relapse, gasparetto says. Serum free light chains test as the kidneys job is to keep protein.
72 849 585 1276 328 888 1286 1076 550 1021 1428 455 1285 666 180 799 1097 905 287 1164 1320 1367 9 246 878 892 117 1043 924 360 720 521 145 1278 531 791 676 806 1320